FHND1002
/ Sino Biopharm
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
October 31, 2025
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of FHND1002 Granules in Patients With Amyotrophic Lateral Sclerosis (ALS)
(ChiCTR)
- P2 | N=180 | Not yet recruiting | Sponsor: Peking University Third Hospital; Peking University Third Hospital
New P2 trial • Amyotrophic Lateral Sclerosis • CNS Disorders
August 23, 2025
FHN-ALS2: FHND1002 for ALS Treatment: Phase 2
(clinicaltrials.gov)
- P2 | N=180 | Not yet recruiting | Sponsor: Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.
New P2 trial • Amyotrophic Lateral Sclerosis • CNS Disorders
January 23, 2025
FHND1002-Ⅰ: Safety, Tolerability, and Pharmacokinetics of FHND1002 Granules in Healthy Adults
(clinicaltrials.gov)
- P1 | N=72 | Enrolling by invitation | Sponsor: Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.
New P1 trial • Amyotrophic Lateral Sclerosis • CNS Disorders
1 to 3
Of
3
Go to page
1